Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details a specific transaction event where nine Directors and PDMRs acquired GSK Ordinary Shares on April 13, 2015.
Management Commentary and Unusual Items
The acquisition of shares occurred through GSK's ShareReward Plan at a price of 1,633.15 pence per Ordinary Share. The transactions included both personal contribution elements and matching elements (GSK contribution). No other risks, contingencies, or unusual items are disclosed in this text.
Important Facts for Investors
- Transaction Date: April 13, 2015.
- Share Price: 1,633.15 pence per Ordinary Share.
- Participants: Nine Directors/PDMRs, including Sir Andrew Witty, acquired shares.
- Volume: Most participants acquired 8 shares under the personal contribution element and 8 shares under the matching element; Dr. P J T Vallance acquired 7 shares under each element.
- Source Limitation: This filing contains no financial performance data for the period.